![Mitchell Chan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mitchell Chan
Financieel Directeur/CFO bij
REGENXBIO INC.
Vermogen: 2 M $ op 30-06-2026
Profiel
Mitchell Chan is currently Director at Maryland Technology Council since 2020 and Executive VP, Chief Financial & Accounting Officer at REGENXBIO, Inc. starting in 2024.
Former roles include Independent Director at Avalo Therapeutics, Inc. from 2021 to 2026, Operating Partner at Catalio Capital Management LP from 2019 to 2021, Chief Financial & Accounting Officer at Viela Bio, Inc. from 2019 to 2021, and Director-Investor Relations at AstraZeneca PLC from 2015 to 2018.
Education includes an MBA from Rotman School of Management and undergraduate and graduate degrees from the University of Toronto.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
REGENXBIO, INC. 0,25% | 06-01-2026 | 127.717 ( 0,25% ) | 2 M $ | 30-06-2026 |
| 06-05-2026 | 3.166 ( 0,01% ) | 58 508 $ | 30-06-2026 |
Actieve functies van Mitchell Chan
| Bedrijven | Functie | Begin |
|---|---|---|
| REGENXBIO INC. | Financieel Directeur/CFO | 16-09-2024 |
Maryland Technology Council
 Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services Function as technology trade association | Directeur/Bestuurslid | 11-03-2020 |
Eerdere bekende functies van Mitchell Chan
| Bedrijven | Functie | Einde |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Directeur/Bestuurslid | 02-06-2026 |
| VIELA BIO, INC. | Financieel Directeur/CFO | 15-03-2021 |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Corporate Officer/Principal | 01-03-2021 |
| ASTRAZENECA PLC | Investor Relations Contact | 01-09-2018 |
Opleiding van Mitchell Chan
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
36
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Rotman School of Management
 Rotman School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
REGENXBIO, Inc.
 REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services Function as technology trade association | Commercial Services |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Finance |
Kies MarketScreener 
